The Effects of Sodium Fluoride and Chlorhexidine Use on Salivary IL-6 and Matrix Metalloproteinase Levels in Children With Active Caries

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age6-8
SponsorGül Keskin

About this trial

This study aims to compare salivary IL-6, MMP-8, MMP-9, and TIMP-1 levels between healthy children and caries-active children, and to evaluate the effects of 5% sodium fluoride (NaF) varnish and 2% chlorhexidine (CHX) used in caries prevention on these biomarkers.

The study will be conducted at Alanya Alaaddin Keykubat University, Faculty of Dentistry, Department of Pediatric Dentistry. Informed consent will be obtained from children and their parents/guardians. Investigator calibration will be performed using Cohen's kappa method prior to data collection. Sample size was calculated assuming 80% power (1-β = 0.80), α = 0.05, and Cohen's d ≈ 0.8, resulting in 20 participants per group using G\*Power 3.1 software.

Study groups: Group A: 5% NaF varnish. Group B: 2% CHX + 5% NaF varnish. Group C: Standard oral hygiene education (negative control). Group D: Caries-free children (biological reference; baseline saliva sampling only).

Saliva samples will be collected at T0 (baseline), T1 (30 minutes post-application), and T2 (1 month). Unstimulated whole saliva will be collected, centrifuged at 5,000 g for 10 minutes at 4°C, and stored at -80°C. IL-6, MMP-8, MMP-9, and TIMP-1 levels will be measured using CE-marked/FDA-approved human saliva ELISA kits.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Children aged 6-8 years with all first permanent molars erupted

For active caries groups (Groups A, B, C): participants must meet at least one of the following criteria: dmft ≥ 6, or presence of at least one active caries lesion with an ICDAS code ≥ 3, or clinical evidence of active caries on ≥ 10 surfaces

For the dmft = 0 reference group (Group D): all surfaces caries-free and non-high-risk individuals (ICDAS II = 0); only baseline (T0) saliva sampling will be performed

No professional topical fluoride application or continuous CHX use within the past 3 months

Disqualifiers

Known allergy to fluoride compounds or varnish components

Behavioral problems that would prevent safe cooperation during application

Regular antibiotic use within the past 1 month

Individuals with infectious diseases

Trial design

Design model

Parallel

Treatments tested in this trial

  • 5% Sodium Fluoride Varnish

    Other intervention

    Teeth are gently air-dried for 30 seconds under isolation with cotton rolls and aspirator. Approximately 0.5 mL of 5% NaF varnish is applied to all tooth surfaces sequentially by quadrant starting from the upper jaw using an applicator tip and left in place for 1 minute. Parents are instructed to restrict water and hard food intake for 1 hour post-application. This is a routine preventive application; no off-label use is involved.

  • 2% Chlorhexidine Pre-Treatment + 5% NaF Varnish

    Other intervention

    Following isolation and air-drying, 2% chlorhexidine solution is applied to the lesion/tooth surfaces using an applicator tip and left in place for 30 seconds. Excess CHX is then absorbed. Precautions are taken to prevent ingestion. This pre-treatment is performed immediately prior to 5% NaF varnish application. This is a routine preventive application; no off-label use is involved.

  • Standard Oral Hygiene Education

    Behavioral

    Children and parents receive standardized oral hygiene education including instruction on twice-daily brushing with fluoride toothpaste, reduction of sugar intake frequency, and a brief parent information brochure. No professional topical agent is applied. Necessary treatment will be offered at the end of the study upon request (wait-list design).

Treatment groups

80 Participants
are divided into 4 treatment groups
Group A: 5% Sodium Fluoride (NaF) VarnishExperimental treatment 1 intervention
Group B: 2% Chlorhexidine Pre-Treatment + 5% NaF VarnishExperimental treatment 1 intervention
Group C: Standard Care / Oral Hygiene EducationActive comparator 1 intervention
Group D: Caries-Free Healthy ControlNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Change in Salivary MMP-8 Levels

Change in salivary matrix metalloproteinase-8 (MMP-8) concentration measured by ELISA from baseline (T0) to post-application (T1) and 1 month post-intervention (T2) , and comparison between caries-active and caries-free groups at baseline. Unstimulated whole saliva samples will be analyzed using CE-marked/FDA-approved human saliva ELISA kits. Results expressed as ng/mL.

Time frame
Baseline (T0), 30 minutes post-application (T1), 1 month post-intervention (T2)
2

Change in Salivary IL-6 Levels

Change in salivary interleukin-6 (IL-6) concentration measured by ELISA from baseline (T0) to post-application (T1) and 1 month post-intervention (T2) , and comparison between caries-active and caries-free groups at baseline. Unstimulated whole saliva samples will be collected, centrifuged at 5,000 g for 10 minutes at 4°C, stored at -80°C, and analyzed using CE-marked/FDA-approved human saliva ELISA kits. Results expressed as pg/mL.

Time frame
Baseline (T0), 30 minutes post-application (T1), 1 month post-intervention (T2)
3

Change in Salivary MMP-9 Levels

Change in salivary matrix metalloproteinase-9 (MMP-9) concentration measured by ELISA from baseline (T0) to post-application (T1) and 1 month post-intervention (T2), and comparison between caries-active and caries-free groups at baseline. Unstimulated whole saliva samples will be analyzed using CE-marked/FDA-approved human saliva ELISA kits. Results expressed as ng/mL.

Time frame
Baseline (T0), 30 minutes post-application (T1), 1 month post-intervention (T2)
4

Change in Salivary TIMP-1 Levels

Change in salivary tissue inhibitor of metalloproteinase-1 (TIMP-1) concentration measured by ELISA from baseline (T0) to post-application (T1) and 1 month post-intervention (T2), and comparison between caries-active and caries-free groups at baseline. Unstimulated whole saliva samples will be analyzed using CE-marked/FDA-approved human saliva ELISA kits. Results expressed as ng/mL.

Time frame
Baseline (T0), 30 minutes post-application (T1), 1 month post-intervention (T2)

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Gül Keskin

Lead sponsor

Alanya Alaaddin Keykubat University

Sponsor institution

Alanya Alaaddin Keykubat University

Collaborator